Sensei Biotherapeutics, Inc. 8-K

What Happened
Sensei Biotherapeutics, Inc. filed an 8-K on May 22, 2026, announcing an update to its planned board reconstitution tied to the company’s 2026 Annual Meeting on June 10, 2026. Dr. Karen Vousden, Ph.D., has asked that her appointment to the board be delayed for personal reasons; the Board intends to consider appointing her in the third or fourth quarter of 2026. If the Required Company Stockholder Matters are approved at the Annual Meeting, the Board intends to appoint Bob Holmen as chair of the Nominating and Corporate Governance Committee effective June 12, 2026, and set the Board size at five directors as of that date.

Key Details

• Filing date: May 22, 2026; Annual Meeting scheduled for June 10, 2026.
• Dr. Karen Vousden’s appointment delayed; Board to consider appointment in Q3 or Q4 2026.
• If stockholder matters are approved, Bob Holmen to become chair of the Nominating & Corporate Governance Committee effective June 12, 2026.
• Board approved to have five directors as of the effective appointment date; appointments dependent on stockholder approval.

Why It Matters
Board composition and committee leadership affect company oversight and governance. Investors should note the delayed timing for Dr. Vousden’s addition and that the planned changes (including Mr. Holmen’s committee chair role and a five-member board) are conditional on stockholder approval at the June 10 meeting. The filing contains forward-looking statements and reinforces that these outcomes are subject to risks and the stockholder vote; there are no financial results reported in this 8-K.